1.Clinical courses after administration of oral corticosteroids in patients with severely cholestatic acute hepatitis A; three cases.
Eileen L YOON ; Hyung Joon YIM ; Seung Young KIM ; Jeong Han KIM ; Ju Han LEE ; Young Sun LEE ; Hyun Jung LEE ; Sung Woo JUNG ; Sang Woo LEE ; Jai Hyun CHOI
The Korean Journal of Hepatology 2010;16(3):329-333
Acute hepatitis A is currently outbreaking in Korea. Although prognosis of acute hepatitis A is generally favorable, a minority of patients are accompanied by fatal complications. Severe cholestasis is one of the important causes of prolonged hospitalization in patients with acute hepatitis A. In such cases, higher chances of additional complications and increased medical costs are inevitable. We report three cases of severely cholestatic hepatitis A, who showed favorable responses to oral corticosteroids. Thirty milligram of prednisolone was initiated and tapered according to the responses. Rapid improvement was observed in all cases without side effects. We suggest that corticosteroid administration can be useful in hepatitis A patients with severe cholestasis who do not show improvement by conservative managements. Clinical trial will be needed to evaluate effectiveness of corticosteroids in these patients.
Acute Disease
;
Administration, Oral
;
Adult
;
Anti-Inflammatory Agents/administration & dosage/*therapeutic use
;
Cholestasis/*drug therapy/etiology/pathology
;
Hepatitis A/*complications/diagnosis
;
Humans
;
Liver/pathology
;
Male
;
Predni
2.A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis.
Jae Young YOON ; Sun Yang MIN ; Ju Yee PARK ; Seung Goun HONG ; Sang Jong PARK ; So Ya PAIK ; Young Min PARK
The Korean Journal of Hepatology 2008;14(1):97-101
Allopurinol-induced hypersensitivity syndrome is characterized by an idiosyncratic reaction involving multiple-organs, which usually begins 2 to 6 weeks after starting allopurinol. In rare cases, the adverse reactions to allopurinol are accompanied by a variety of liver injury, such as reactive hepatitis, granulomatous hepatitis, vanishing bile duct syndrome, or fulminant hepatic failure. Here we report a case with granulomatous hepatitis and ductopenia. A 69-year-old man with chronic renal failure, hyperuricemia, and previously normal liver function presented with jaundice, skin rash, and fever 2 weeks after taking allopurinol (200 mg/day). In histopathology, a liver biopsy specimen showed mild spotty necrosis of hepatocytes, marked cholestasis in parenchyma, and some granulomas in the portal area. There were vacuolar degeneration in the interlobular bile ducts and ductopenia in the portal tracts. Pathologic criteria strongly suggested the presence of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. The patient fully recovered following the early administration of systemic corticosteroid therapy.
Aged
;
Allopurinol/*adverse effects/therapeutic use
;
Antimetabolites/*adverse effects/therapeutic use
;
Bile Duct Diseases/*chemically induced/diagnosis/pathology
;
Bile Ducts, Intrahepatic/*drug effects/pathology
;
Cholestasis/*chemically induced/diagnosis/pathology
;
Drug Eruptions/pathology
;
Granuloma/*chemically induced/pathology
;
Hepatitis, Toxic/*pathology
;
Humans
;
Kidney Failure, Chronic/complications/drug therapy
;
Male
3.Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report.
Hee Sup KIM ; Sook Hyang JEONG ; Je Hyuck JANG ; Hyung Joon MYUNG ; Jin Wook KIM ; Soo Mee BANG ; Sang Hoon SONG ; Haeryoung KIM ; Hae Sun YUN
The Korean Journal of Hepatology 2011;17(4):323-327
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Anti-Inflammatory Agents/therapeutic use
;
Cholestasis/*diagnosis/drug therapy/pathology
;
Coinfection/*diagnosis
;
Genotype
;
Hepatitis A/complications/*diagnosis/genetics
;
Hepatitis E/complications/*diagnosis/genetics
;
Humans
;
Immunoglobulin M/blood
;
Liver/pathology/virology
;
Male
;
Prednisolone/therapeutic use
;
RNA, Viral/blood
4.Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation.
Byung Kook KIM ; So Young KWON ; Soon Young KO ; Won Hyeok CHOE ; Chang Hong LEE ; He Seong HAN ; Seong Hwan CHANG
The Korean Journal of Hepatology 2008;14(4):519-524
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon alpha-2a and ribavirin.
Antiviral Agents/*administration & dosage
;
Cholestasis, Intrahepatic/*diagnosis/pathology
;
Combined Modality Therapy
;
Hepacivirus/drug effects
;
Hepatitis C, Chronic/diagnosis/*drug therapy/pathology
;
Humans
;
Interferon Alfa-2a/*administration & dosage
;
*Liver Transplantation
;
Male
;
Middle Aged
;
Polyethylene Glycols/*administration & dosage
;
RNA, Viral/analysis
;
Recurrence
;
Ribavirin/*administration & dosage
;
Tomography, X-Ray Computed
5.Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report.
Jihyun AN ; Joo Ho LEE ; Hyojeong LEE ; Eunsil YU ; Dan Bi LEE ; Ju Hyun SHIM ; Sunyoung YOON ; Yumi LEE ; Soeun PARK ; Han Chu LEE
The Korean Journal of Hepatology 2012;18(1):84-88
Hepatitis A virus (HAV) infections occur predominantly in children, and are usually self-limiting. However, 75-95% of the infections in adults are symptomatic (mostly with jaundice), with the illness symptoms usually persisting for a few weeks. Atypical manifestations include relapsing hepatitis, prolonged cholestasis, and complications involving renal injury. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, drug-induced hypersensitivity reaction characterized by skin rash, fever, lymph-node enlargement, and internal organ involvement. We describe a 22-year-old male who presented with acute kidney injury and was diagnosed with prolonged cholestatic hepatitis A. The patient also developed DRESS syndrome due to antibiotic and/or antiviral treatment. To our knowledge, this is the first report of histopathologically confirmed DRESS syndrome due to antibiotic and/or antiviral treatment following HAV infection with cholestatic features and renal injury.
Acute Kidney Injury/diagnosis
;
Anti-Bacterial Agents/*adverse effects/therapeutic use
;
Cefotaxime/adverse effects/therapeutic use
;
Cholestasis/complications/*diagnosis
;
Cytomegalovirus/genetics
;
Cytomegalovirus Infections/drug therapy/virology
;
DNA, Viral/analysis
;
Eosinophilia/etiology
;
Exanthema/*chemically induced/pathology
;
Ganciclovir/therapeutic use
;
Hepatitis A/complications/*diagnosis/drug therapy
;
Humans
;
Hydrocortisone/therapeutic use
;
Immunoglobulins/therapeutic use
;
Male
;
Syndrome
;
Young Adult
6.A Korean patient with Guillain-Barré syndrome following acute hepatitis E whose cholestasis resolved with steroid therapy.
Sung Bok JI ; Sang Soo LEE ; Hee Cheul JUNG ; Hong Jun KIM ; Hyun Jin KIM ; Tae Hyo KIM ; Woon Tae JUNG ; Ok Jae LEE ; Dae Hyun SONG
Clinical and Molecular Hepatology 2016;22(3):396-399
Autochthonous hepatitis E virus (HEV) is an emerging pathogen in developed countries, and several cases of acute HEV infection have been reported in South Korea. However, there have been no reports on HEV-associated Guillain-Barré syndrome (GBS) in Korea. We recently experienced the case of a 58-year-old Korean male with acute HEV infection after ingesting raw deer meat. Persistent cholestasis was resolved by the administration of prednisolone. At 2.5 months after the clinical presentation of HEV infection, the patient developed weakness of the lower limbs, and was diagnosed with GBS associated with acute hepatitis E. To our knowledge, this is the second report on supportive steroid therapy for persistent cholestasis due to hepatitis E, and the first report of GBS in a Korean patient with acute HEV infection.
Acute Disease
;
Alanine Transaminase/blood
;
Antibodies, Viral/blood
;
Aspartate Aminotransferases/blood
;
Bilirubin/analysis
;
Cholestasis/*drug therapy
;
Guillain-Barre Syndrome/complications/*diagnosis
;
Hepatitis E/*diagnosis/etiology
;
Hepatitis E virus/immunology
;
Humans
;
Immunoglobulin M/blood
;
Liver/pathology
;
Male
;
Middle Aged
;
Prednisolone/therapeutic use
;
Republic of Korea
;
Steroids/*therapeutic use